
News release: FOR IMMEDIATE RELEASE

J.P. MORGAN APPOINTED DEPOSITARY BANK BY CHINA NUOKANG BIO-PHARMACEUTICAL

Hong Kong, January 14, 2010 – J.P. Morgan announced today that it has been appointed depositary bank by China Nuokang Bio-Pharmaceutical Inc. ('Nuokang') in connection with Nuokang's recent initial public offering of 5,000,000 American Depositary Shares.

Nuokang is a leading bio-pharmaceutical company in China, focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. The company provides a diversified portfolio of products to more than 2,400 hospitals in China.

"Throughout the entire IPO process, J.P. Morgan's depositary receipts team was extremely responsive to our needs. We look forward to partnering with J.P. Morgan to further develop our ADR program and to support our business expansion going forward," said Xue Baizhong, chairman and chief executive officer of China Nuokang Bio-Pharmaceutical.

"We are pleased to be appointed depositary bank by China Nuokang. We believe that our extensive experience in helping China-based companies enter the U.S. market will be instrumental in the continued success of Nuokang's ADR program," added Kenneth Tse, Asia Pacific head of J.P. Morgan's depositary receipts group.

J.P. Morgan is committed to working closely with its clients to design and implement customized depositary receipt ('DR') programs to achieve their strategic goals and facilitate DR liquidity.

J.P. Morgan launched the first depositary receipt program in Asia in 1961 for Sony, and serves as depositary bank for leading companies throughout the region. J.P. Morgan provides a full range of American Depositary Receipt ('ADR') and Global Depositary Receipt ('GDR') services to issuers seeking to have their equity traded on exchanges beyond their home markets.

For market information on depositary receipts and international equities, please go to J.P. Morgan's award-winning web site www.adr.com. More information on J.P. Morgan's depositary receipt services is also available on www.jpmorgan.com/visit/adr.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) is a leading bio-pharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. The company provides a diversified portfolio of products to more than 2,400 hospitals in China. Please visit www.nkbp.com or www.lnnk.com for more information.

About J.P. Morgan Worldwide Securities Services

J.P. Morgan Worldwide Securities Services (WSS) is a premier securities servicing provider that helps institutional investors, alternative asset managers, broker dealers and equity issuers optimize efficiency, mitigate risk and enhance revenue. A division of JPMorgan Chase Bank, N.A. (NYSE: JPM), WSS leverages the firm's unparalleled scale, leading technology and deep industry expertise to service investments around the world. It has \$14.9 trillion in assets under custody and \$5.1 trillion in funds under administration. For more information, go to www.jpmorgan.com/visit/wss.

About JPMorgan Chase & Co.

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of \$2 trillion and operations in more than 60 countries. The firm is a leader in investment banking, financial services for consumers, small business and commercial banking, financial transaction processing, asset management and private equity. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of consumers in the United States and many of the world's most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands. In Asia Pacific, J.P. Morgan operates through 26 offices in 15

countries and has developed its wholesale banking franchise during a history of almost 160 years in the region. More information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

#